170 results on '"McBride, Helen"'
Search Results
2. ORAI1 and ORAI2 modulate murine neutrophil calcium signaling, cellular activation, and host defense
3. Non-clinical similarity of biosimilar ABP 798 with rituximab reference product
4. Binding affinity determination of therapeutic antibodies to membrane protein targets: Kinetic Exclusion Assay using cellular membranes for anti-CD20 antibody
5. Impact of Precipitation of Antibody Therapeutics After Subcutaneous Injection on Pharmacokinetics and Immunogenicity
6. A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501
7. Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab
8. Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product
9. Chapter 11 - Kinetic exclusion assay using cellular membranes for affinity determination of anti-CD20 antibody
10. Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab
11. Murine collagen antibody induced arthritis (CAIA) and primary mouse hepatocyte culture as models to study cytochrome P450 suppression
12. Contributors
13. Use of nonclinical toxicity studies to support biosimilar antibody development
14. Tagging of Plant Potyvirus Replication and Movement by Insertion of β-Glucuronidase into the Viral Polyprotein
15. Wnt signaling components in the chicken intestinal tract
16. Young Scientist: Women mentoring women
17. The protein kinase Pho85 is required for asymmetric accumulation of the Ash1 protein in Saccharomyces cerevisiae
18. Tagging of plant potyvirus replication and movement by insertion of beta-glucoronidase into the viral polyprotein
19. Interactions between Pho85 cyclin-dependent kinase complexes and the Swi5 transcription factor in budding yeast
20. Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar
21. Correction: Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
22. Totality of evidence in development of the bevacizumab biosimilar ABP 215: Central and investigator evaluation of efficacy from the MAPLE study.
23. Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
24. ORAI1 and ORAI2 modulate murine neutrophil calcium signaling, cellular activation, and host defense.
25. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab
26. Distinct Regions of the Swi5 and Ace2 Transcription Factors Are Required for Specific Gene Activation
27. Novel protein therapeutic joint retention strategy based on collagen-binding Avimers
28. Bone CLARITY: Clearing, imaging, and computational analysis of osteoprogenitors within intact bone marrow
29. ABP 501: Matching the Critical Functions of Adalimumab
30. Modeling Therapeutic Antibody–Small Molecule Drug-Drug Interactions Using a Three-Dimensional Perfusable Human Liver Coculture Platform
31. Orai1 enhances muscle endurance by promoting fatigue‐resistant type I fiber content but not through acute store‐operated Ca2+entry
32. Sa1858 ABP 501, a Proposed Biosimilar to Adalimumab: Functional Similarity Adds to the Totality of Evidence in Support for Biosimilarity in All Approved Indications of Use
33. Selective ORAI1 Inhibition Ameliorates Autoimmune Central Nervous System Inflammation by Suppressing Effector but Not Regulatory T Cell Function
34. Novel protein therapeutic joint retention strategy based on collagen‐binding Avimers.
35. Functional Similarity of Proposed Biosimilar ABP 798 with Rituximab
36. Mo1733 - ABP 501: Matching the Critical Functions of Adalimumab
37. Part 2: Structure–activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38α mitogen-activated protein kinase
38. Expression of ORAI1, a Plasma Membrane Resident Subunit of the CRAC Channel, in Rodent and Non-rodent Species
39. Inhibition of CRAC with a human anti-ORAI1 monoclonal antibody inhibits T-cell-derived cytokine production but fails to inhibit a T-cell-dependent antibody response in the cynomolgus monkey
40. Degradation of the transcription factor Gcn4 requires the kinase Pho85 and the SCFCDC4 ubiquitin-ligase complex
41. Part 1: Structure–Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38α mitogen-activated protein kinase
42. Generation and Characterization of Fully Human Monoclonal Antibodies Against Human Orai1 for Autoimmune Disease
43. Orai1 enhances muscle endurance by promoting fatigue-resistant type I fiber content but not through acute store-operated Ca2+ entry.
44. Discovery and in Vivo Evaluation of Dual PI3Kβ/δ Inhibitors
45. Discovery of Pyridazinopyridinones as Potent and Selective p38 Mitogen-Activated Protein Kinase Inhibitors
46. Nuclear imaging of autoimmunity: Focus on IBD and RA
47. Discovery and Evaluation of 7-Alkyl-1,5-bis-aryl-pyrazolopyridinones as Highly Potent, Selective, and Orally Efficacious Inhibitors of p38α Mitogen-Activated Protein Kinase⊥⊥ Atomic coordinates and structure factors for crystal structure of compound3dwith p38α can be accessed using PDB code 3LHJ.
48. Portable Appreciation Facilities
49. Inhibition of CRAC with a human anti-ORAI1 monoclonal antibody inhibits T-cell-derived cytokine production but fails to inhibit a T-cell-dependent antibody response in the cynomolgus monkey.
50. Women mentoring women
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.